Company Profile

Renovacor, Inc. is a preclinical-stage gene therapy company. The Company is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. The Company's therapeutic focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM). The Company is also conducting preclinical studies exploring the ability of a BAG3 gene therapy to treat patients suffering from DCM caused by BAG3 haploinsufficiency. The Company's preclinical strategy is to advance earlier stage research programs of its BAG3 gene therapy. Its research and discovery programs include BAG3- mediated diseases associated with the cardiovascular system and the central nervous system.

Employees

Sector

Biotechnology & Medical Research

More about the company

01/22/01	Renovacor, Inc.(NYSEAM:RCOR) dropped from S&P TMI Index	CI
01/22/01	Rocket Pharmaceuticals, Inc. completed the acquisition of Renovacor, Inc. from RTW Investments, LP, Chardan Investments 2, LLC and others,	CI
11/22/11	Renovacor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
21/22/21	Baird Downgrades Renovacor to Neutral From Outperform, Adjusts Price Target to $2.75 From $9	MT
21/22/21	BTIG Downgrades Renovacor to Neutral From Buy	MT
21/22/21	Ladenburg Thalmann Downgrades Renovacor to Neutral From Buy, Adjusts Price Target to $2.60 From $22	MT
20/22/20	Wall Street Set to Open Lower Ahead of Fed Meeting	MT
20/22/20	US Futures Lower as Investors Gird for Another Fed Rate Increase	MT
20/22/20	Renovacor, Inc., Rocket Pharmaceuticals, Inc. - M&A Call
20/22/20	Top Premarket Gainers	MT
20/22/20	Rocket Pharmaceuticals to Acquire Renovacor in $53 Million All-Stock Deal	MT
20/22/20	Rocket Pharmaceuticals, Inc. entered into a definitive agreement to acquire Renovacor, Inc. from RTW Investments, LP, Chardan Investments 2, LLC and others for $49.1 million.	CI
14/22/14	BTIG Starts Renovacor at Buy With $8 Price Target	MT

21/22/21	Baird Downgrades Renovacor to Neutral From Outperform, Adjusts Price Target to $2.75 From $9	MT
21/22/21	BTIG Downgrades Renovacor to Neutral From Buy	MT
21/22/21	Ladenburg Thalmann Downgrades Renovacor to Neutral From Buy, Adjusts Price Target to $2.60 From $22	MT
14/22/14	BTIG Starts Renovacor at Buy With $8 Price Target	MT
13/22/13	Baird Initiates Renovacor at Outperform With $9 Price Target	MT

11/22/11	RENOVACOR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
14/22/14	RENOVACOR, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
11/22/11	Renovacor Announces Upcoming Presentation at the 29th European Society of Gene and Cell Therapy Congress	AQ
11/22/11	Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress	BU
27/22/27	Renovacor Announces Upcoming Presentation at Keystone Symposia's Heart Failure, Mechanisms and Therapies Conference	AQ

Manager	Title	Age	Since
Jordan Shin CTO	Chief Tech/Sci/R&D Officer	-	-
Kumar Dhanasekharan CTO	Chief Tech/Sci/R&D Officer	-	04/10/2021
Elizabeth White COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Gbola Amusa BRD	Director/Board Member	52	02/09/2021
Edward Benz BRD	Director/Board Member	80	01/07/2017
Gregory Covino BRD	Director/Board Member	61	02/09/2021

Renovacor, Inc. Share Price

Stocks

RCOR

US75989E1064

Biotechnology & Medical Research

Latest news: Renovacor, Inc.

Analysts' recommendations: Renovacor, Inc.

Press Releases: Renovacor, Inc.

Quotes and Performance

Managers and Directors: Renovacor, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/12/22	Joseph Carroll	Issuer sale	Controller/Auditor	79,429	0.4599%
01/12/22	Jonas Grossman	Issuer sale	Director	4,30,657	2.4938%
01/12/22	Gbola Amusa	Issuer sale	Director	3,14,588	1.8216%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RENOVACOR, INC.	+4.92%	+7.93%	-	-	5.37Cr
LONZA GROUP AG	+2.64%	+7.07%	+11.87%	+38.40%	4.8TCr
IQVIA HOLDINGS INC.	+0.22%	+0.40%	+49.94%	+37.06%	4.45TCr
REVOLUTION MEDICINES, INC.	-1.58%	+4.66%	+337.90%	+614.38%	4.39TCr
BEONE MEDICINES AG	+1.70%	+0.36%	+10.27%	+99.27%	4.1TCr
CELLTRION, INC.	+0.51%	-0.61%	+5.18%	+46.87%	2.99TCr
MEDPACE HOLDINGS, INC.	-0.48%	-1.32%	+23.00%	+150.01%	1.73TCr
TEMPUS AI, INC.	+0.08%	+9.03%	+8.29%	-	1.53TCr
EUROFINS SCIENTIFIC SE	+1.76%	+2.98%	+29.13%	+45.78%	1.53TCr
ASCENDIS PHARMA A/S	+1.97%	-3.17%	-	-	1.48TCr
Average	+1.10%	+2.46%	+59.45%	+147.39%	3TCr
Weighted average by Cap.	+0.67%	+2.97%	+75.17%	+163.62%